Table 3.

The Relationship Between CLDN8/AR Co-Expression with Clinicopathological Features in Breast Cancer Patients

Factors	Total	CLDN8+/AR+		Other Expression		P
		N	%	N	%
All	142	52	36.7	90	63.3
Age (years)						0.570
≤50	59	20	33.9	39	66.1
>50	83	32	38.6	51	61.4
T Stage						0.561
T1–T2	94	36	38.3	58	61.7
T3	48	16	33.3	32	66.7
N Stage						0.007*
N0	86	39	45.3	47	54.7
N1–3	56	13	23.2	43	76.8
Histologic Grade						0.017*
G1–G2	110	46	41.8	64	58.2
G3	32	6	18.8	26	81.2
Estrogen Receptor						0.019*
Negative	35	7	20.0	28	80.0
Positive	107	45	42.1	62	57.9
Progesterone Receptor						0.015*
Negative	48	11	22.9	37	77.1
Positive	94	41	43.6	53	56.4
HER2						0.508
Negative	99	38	38.4	61	61.6
Positive	43	14	32.6	29	67.4
Ki-67 Index (%)						0.038*
≤20	50	24	48.0	26	52.0
>20	92	28	30.4	64	69.6

Note: *Difference was statistically significant.

Abbreviations: CLDN8, claudin-8; AR, androgen receptor.